Cellumen and RheoGene Enter Into Non-Exclusive Licensing Deal

Cellumen and RheoGene announced recently that they have entered into a non-exclusive commercial licensing agreement under which Cellumen will use RheoGene's RheoSwitch inducible gene regulation technology to develop cell biology screening products.

The products will include reagents for high content screening and stable cell lines. In addition, the companies will collaborate on the development and validation of mammalian cell lines to be used in Cellumen's cell biology profiling assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.